date,title,source
Nov-01-18,Urovant Sciences Announces Publication of Phase 2b Data for Vibegron in European Urology,Business Wire
Nov-05-18,Urovant Sciences to Report 2018 Second Fiscal Quarter Financial Results,Business Wire
Nov-08-18,Urovant Sciences Completes Patient Enrollment in Phase 3 Pivotal Trial Studying Vibegron for Overactive Bladder,Business Wire
Nov-12-18,"Urovant Sciences Reports Financial Results for the Second Fiscal Quarter Ended September 30, 2018 and Provides Corporate Update",Business Wire
Nov-19-18,Urovant Sciences Announces Participation in Piper Jaffray Healthcare Conference,Business Wire
Dec-19-18,Urovant Sciences to Present at the J.P. Morgan 37th Annual Healthcare Conference,Business Wire
Jan-02-19,Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference,PR Newswire
Jan-03-19,Urovant Sciences Initiates Patient Enrollment in Phase 2a Clinical Trial for Vibegron in Patients with Abdominal Pain Due to Irritable Bowel Syndrome,Business Wire
Jan-15-19,"Urovant Sciences to Host R&D Day for Investors and Analysts on February 7, 2019",Business Wire
Feb-06-19,Urovant Sciences to Report 2018 Third Fiscal Quarter Financial Results,Business Wire
Feb-13-19,"Urovant Sciences Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2018",Business Wire
Feb-22-19,Urovant Sciences Enters into Flexible Agreement for up to $100 Million Debt Financing with Hercules Capital,Business Wire
Feb-26-19,Codexis Inc (CDXS) Q4 2018 Earnings Conference Call Transcript,Motley Fool
Mar-06-19,Urovant Sciences Appoints James Robinson to its Board of Directors,Business Wire
Mar-07-19,Urovant Sciences to Present at the Cowen and Company 39th Annual Healthcare Conference,Business Wire
Mar-18-19,Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder,Business Wire
Mar-19-19,Here's Why Urovant Sciences Got Whacked on &quot;Positive&quot; Clinical Trial Data,Motley Fool
Mar-19-19,Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder,Business Wire
Mar-27-19,Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia,Business Wire
Apr-29-19,Urovant Sciences to Present Late-Breaking Data on Vibegron During Plenary Session at the American Urological Association Annual Meeting,Business Wire
May-06-19,Urovant Sciences Presents Positive Pivotal Data for Vibegron During Plenary Session at American Urological Association Annual Meeting,Business Wire
